中药及营养、运动处方综合干预骨龄正常和偏大的身材偏矮儿童的研究

发布时间：2018-03-02 12:47

本文选题：身材偏矮　切入点：中药及营养　出处：《山东中医药大学》2012年硕士论文　论文类型：学位论文

【摘要】：目的：本课题旨在观察中药及营养、运动处方综合干预骨龄正常和偏大的身材偏矮儿童的临床疗效；比较此综合干预法与重组人生长激素的优越性。方法：选取骨龄正常和偏大的身材偏矮儿童219例，随机分为干预1组、干预2组、空白对照组，各组再根据骨龄分为三个年龄段：6~11岁骨龄、~15岁骨龄、~18岁骨龄。干预1组给予中药及营养、运动处方综合干预，干预2组给予国产r-hGH治疗，空白对照组未进行任何治疗和干预，，疗程为12个月。治疗前及疗程结束后分别检测儿童身高、体重、骨龄，疗程结束后计算年生长速度、骨成熟变化情况、费用。采用单因素方差分析、独立样本t检验统计学方法分析后比较三组治疗12个月后的身高、体重、骨龄、年生长速率、骨成熟变化情况，比较干预1组中骨龄正常与骨龄偏大儿童12个月后身高、年生长速度的变化；比较干预1组与干预2组的治疗费用情况；比较三组儿童发展为矮小症的比率。结果：1.干预1组与空白对照组12月后的身高有显著性差异（P0.05），6~11岁骨龄身高分别为：138.27±7.43cm、132.63±6.29cm；~15岁骨龄身高分别为：152.60±7.60cm、148.92±7.12cm；~18岁骨龄身高分别为：162.83±7.02cm、159.25±5.69cm。 2.干预1组、干预2组、空白对照组三组身高年生长速率比较有显著性差异（P0.05），6~11岁骨龄分别为：9.86±1.41、7.00±0.85、4.80±0.75；~15岁骨龄分别为：8.18±2.55、6.90±2.00、4.46±1.36；~18岁骨龄分别为：4.69±1.81、3.40±0.87、2.15±0.85。 3.干预1组、干预2组、对照组治疗后体重、骨龄、骨成熟变化情况无显著性差异（P0.05）。 4.干预1组中骨龄正常儿童身高年生长速率（7.93±2.64cm/年）与骨龄偏大儿童年生长速率（4.90±2.80cm/年）有显著行差异（P0.05）。 5.干预1组与干预2组治疗12个月后总费用比较有显著性差异（P0.05）。 6.干预1组、干预2组12个月后未发现矮小症儿童，空白对照组发现6例发展为矮小症。结论：中药及营养、运动处方综合干预骨龄正常和偏大的身材偏矮儿童临床疗效显著，效果优于重组人生长激素；中药及营养、运动处方综合干预对骨龄正常的身材矮小儿童效果更佳。中药及营养、运动处方综合干预12个月的费用明显低于重组人生长激素治疗的同期费用。如果对身材偏矮儿童不进行任何干预和治疗，部分偏矮儿童将发展为矮小症。
[Abstract]:Objective: the purpose of this study is to observe the clinical efficacy of Chinese medicine and nutrition and exercise prescription intervention in children with normal bone age and too short stature, and compare the superiority of this comprehensive intervention and recombinant human growth hormone.
Methods: 219 children with normal bone age and larger body size were selected and randomly divided into intervention group 1, intervention group 2, blank control group. According to bone age, each group was divided into three age groups: 6~11 years old bone age, ~15 years old bone age, ~18 age bone age.
1 the intervention group was treated with Chinese medicine and nutrition, exercise prescription intervention, intervention group received 2 domestic r-hGH treatment, control group without any treatment and intervention treatment for 12 months. Before and after treatment were detected in children's height, weight, bone age, after the end of treatment to calculate the annual growth rate, bone maturation changes cost, by ANOVA, independent samples t test analysis method were compared between the three groups after 12 months after treatment the height, weight, age, growth rate, bone maturation changes, compared 1 groups of normal bone age and bone age of children is 12 months after the height of intervention, changes in growth speed; intervention between 1 group and 2 group intervention treatment costs; the ratio between the three groups for the development of children of short stature.
Results: 1. 1 intervention group and blank control group in December after the height had significant difference (P0.05), 6~11 years old age height were: 138.27 + 7.43cm, 132.63 + 6.29cm; ~15 years old age height were: 152.60 + 7.60cm, 148.92 + 7.12cm; ~18 years old age height were: 162.83 + 7.02cm, 159.25 + 5.69cm.
2. intervention group 1, group 2, control group three group height growth rate had significant difference (P0.05), 6~11 years old age were: 9.86 + 1.41,7.00 + 0.85,4.80 + 0.75; ~15 years old age were: 8.18 + 2.55,6.90 + 2.00,4.46 + 1.36; ~18 years old age were: 4.69 + 1.81,3.40 + 0.87,2.15 + 0.85.
3. intervention in 1 groups, intervention in 2 groups, the control group after treatment weight, bone age, bone maturity, no significant difference (P0.05).
4. intervention in 1 groups, the growth rate of body height (7.93 + 2.64cm/ years) in skeletal age normal children was significantly different from that in skeletal age children (4.90 + 2.80cm/ years) (P0.05).
There was a significant difference in total cost between the 1 groups in the 5. intervention group and the intervention of the 2 groups for 12 months (P0.05).
6. the 1 groups were intervened and the children were not found short of dwarfism after 12 months of intervention. The blank control group found 6 cases developed into dwarfism.
Conclusion: the traditional Chinese medicine and nutrition, exercise prescription intervention bone age normal and too large short stature children's curative effect is better than that of recombinant human growth hormone; traditional Chinese medicine and better nutrition, exercise prescription intervention on bone age normal children with short stature. The effect of traditional Chinese medicine and nutrition, exercise prescription intervention costs over the same period of 12 months was significantly lower than that of recombinant human growth hormone treatment. If the short stature children without any intervention and treatment, the partial short of children will be developed for short stature.

【学位授予单位】：山东中医药大学
【学位级别】：硕士
【学位授予年份】：2012
【分类号】：R725.8

【参考文献】